PD-L1 testing across tumor indications · INDICATION PD-L1 testing across tumor indications...

INDICATION PD-L1 testing across tumor indications TREATMENT ALGORITHM CLONES CUT-OFF References: 1. Dolled-Filhart M., et al. Development of a companion diagnostic for pembrolizumab in non–small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med. 2016;140(11):1243–1249. 2. Reck M., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer. N Engl J Med. 2016; 375(19):1823-1833. 3. Antonia S.J., et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018; 379:2342-2350. 4. Herbst R.S., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. 5. Balar A.V., et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017; 18(11):1483–1492. 6. Balar A.V., et.al. Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicenter, phase 2 trial. Lancet 2017;389(10064):67-76. 7. Burtness B., et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomized, open-label phase 3 study. Lancet. 2019; 394(10212):1915-1928. 8. Schmid P., et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018; 379(22):2108-2121. Abbreviations: TPS: Tumor Proportion Score; CPS: Combined Positive Score; Cis-ineligible UC: cisplatin-ineligible urothelial cancer; LDT: Laboratory Developed Test; IC: Immune cells; 5-FU: 5-fluorouracil ≥ 50% ≥ 1% CPS • 22C3 PharmDx kit • 22C3 LDT ≥ 10 ≥ 5% Ventana PD-L1 (SP142) Assay Non-small cell lung cancer 2L Urothelial Carcinoma IC Responsible editor: Belgian Society of Pathology Date of last revision: 12/2019 • 22C3 PharmDx kit • 22C3 LDT • Ventana PD-L1 (SP263) Assay Please consult the prescribing information before prescribing, via www.fagg.be ≥ 1% IC Triple-Negative Breast Cancer 1L Atezolizumab + nab-paclitaxel 8 Head and Neck Squamous Cell Carcinoma ≥ 1* CPS 1L Pembrolizumab 7 with or without platinum+5-FU • 22C3 PharmDx kit • 22C3 LDT *To be reported as CPS<1, CPS≥1 or CPS≥20 TPS Pembrolizumab 1,2 Pembrolizumab 4 Durvalumab 3 DISEASE STAGE ≥ 1% Metastatic Locally advanced, unresectable Locally advanced or metastatic 1L Atezolizumab 6 1L Locally advanced or metastatic Cisplatin-ineligible Ventana PD-L1 (SP142) Assay Metastatic or unresectable recurrent Metastatic Responsible editor: Belgian Society of Pathology Pembrolizumab 5

Upload
others
Category

Documents
view
4
download
0

Embed Size (px):

Transcript of PD-L1 testing across tumor indications · INDICATION PD-L1 testing across tumor indications...

INDICATION

PD-L1 testing across tumor indications

TREATMENT ALGORITHM CLONES CUT-OFF

References: 1. Dolled-Filhart M., et al. Development of a companion diagnostic for pembrolizumab in non–small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med. 2016;140(11):1243–1249.2. Reck M., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer. N Engl J Med. 2016; 375(19):1823-1833.3. Antonia S.J., et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018; 379:2342-2350.4. Herbst R.S., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. 5. Balar A.V., et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;

18(11):1483–1492.6. Balar A.V., et.al. Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicenter, phase 2 trial. Lancet 2017;389(10064):67-76.7. Burtness B., et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomized, open-label phase 3

study. Lancet. 2019; 394(10212):1915-1928.8. Schmid P., et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018; 379(22):2108-2121.

Abbreviations: TPS: Tumor Proportion Score; CPS: Combined Positive Score; Cis-ineligible UC: cisplatin-ineligible urothelial cancer; LDT: Laboratory Developed Test; IC: Immune cells; 5-FU: 5-fluorouracil

≥ 50%

≥ 1%

CPS• 22C3 PharmDx kit• 22C3 LDT

≥ 10

≥ 5%Ventana PD-L1 (SP142) Assay

Non-small cell lung cancer

Urothelial Carcinoma

Responsible editor: Belgian Society of Pathology

Date of last revision: 12/2019

• 22C3 PharmDx kit• 22C3 LDT• Ventana PD-L1

(SP263) Assay

Please consult the prescribing information before prescribing, via www.fagg.be